Neervannan Seshadri 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 5, 2026
Insider Transaction Report
Form 4
Neervannan Seshadri
Chief Operating Officer
Transactions
- Sale
Common Stock
[F1]2026-03-04$76.67/sh−8,366$641,421→ 70,817 total
Holdings
- 475(indirect: By daughter)
Common Stock
[F2]
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
- [F2]This holding balance is related to the Reporting Person's daughter who shares the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by his daughter, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact|2026-03-05